Publications & Conference Abstracts

At Braeburn, we are leveraging our focus on opioid use disorder to work with the healthcare community and advance research, education and support to help end the opioid epidemic.

Peer-Reviewed Publications

  • Albayaty, M., Linden, M., Olsson, H. et al. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. Adv Ther 34, 560–575 (2017). doi.org/10.1007/s12325-016-0472-9
  • Haasen C, Linden M, Tiberg F. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. J Subst Abuse Treat. 2017;78:22‐29. doi:10.1016/j.jsat.2017.04.008
  • Walsh SL, Comer SD, Lofwall MR, et al. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(9):894–902. doi:10.1001/jamapsychiatry.2017.1874
  • Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(6):764‐773. doi:10.1001/jamainternmed.2018.1052
  • Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416‐1426. doi:10.1111/add.14636

Conference Abstracts

2020

  • Budilovsky-Kelley N. (2020) Prevalence and Burden of Untreated and Under-Treated Opioid Use Disorder: Retrospective Database Analysis. Academy of Managed Care Pharmacy (AMCP), April 21-24, Virtual.
  • Frost M, Bailey G, Tiberg F, Hjelmstrom P, Budilovsky-Kelley N. (2020) Effect of SC Weekly/Monthly Buprenorphine (CAM2038) Dose on OUD Treatment Outcomes. Annual meeting of the American Society of Addiction Medicine (ASAM), April 3-5, Virtual.

2019

  • Nunes E, Comer S, Lofwall M, Walsh S, Peterson S, Budilovsky-Kelley N, Tiberg F, Kim S. (2019) Injectable Weekly and Monthly Buprenorphine in the Outpatient Treatment of Fentanyl Users with Opioid Use Disorder. American Academy of Addiction Psychiatry (AAAP) Annual Meeting, December 5-8, San Diego, CA.
  • Nunes E, Comer S, Lofwall M, Walsh S, Peterson S, Budilovsky-Kelley N, Tiberg F, Kim S. (2019) Injectable weekly and monthly buprenorphine in the outpatient treatment of fentanyl users with opioid use disorder (OUD). The College on Problems of Drug Dependence (CPDD), June 15-19, San Antonio, TX.
  • Bailey G, Frost M, Kim S, Budilovsky-Kelley N, Tiberg F. (2019) Patient Satisfaction With Injectable Weekly and Monthly Buprenorphine and Buprenorphine Treatment Experience. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 28-31, Scottsdale, AZ.
  • Budilovsky-Kelley N, Kim S, Polson M, Williams T. (2019) Clinical and Economic Impact of Relapse in Patients with Opioid Use Disorder in the US. The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Meeting, May 18-22, New Orleans, LA.
  • Nunes E, Comer S, Lofwall M, Walsh S, Peterson S, Budilovsky-Kelley N, Tiberg F, Kim S. (2019) Correlates Of Fentanyl Use In A Controlled Trial Of Injectable Weekly/Monthly Buprenorphine. Annual Meeting of the American Society of Addiction Medicine (ASAM), April 4-7, Orlando, FL.
  • Carter J, Frost M, Budilovsky-Kelley N. (2019) Quality of life in adult outpatients with opioid use disorder treated with long-acting subcutaneous injection buprenorphine depot: Results from an open-label multicenter clinical trial. Academy of Managed Care Pharmacy (AMCP), March 25-28, San Diego, CA.

2018

  • Frost M, Tiberg F, Carter J, Rasmussen M, Kim S, Rasmus J, Budilovsky-Kelley N. (2018) Impacts of relapse status and responder rate on quality of life in adults treated with CAM2038 for opioid use disorder. American Academy of Addiction Psychiatry (AAAP) Annual Meeting, December 6-9, Bonita Springs, FL.
  • Frost M, Tiberg F, Carter J, Rasmussen M, Kim S, Rasmus J, Budilovsky-Kelley N. (2018) Patient satisfaction and experience with weekly/monthly sustained-release injectable buprenorphine. American Academy of Addiction Psychiatry (AAAP) Annual Meeting, December 6-9, Bonita Springs, FL.
  • Jensen R, Rasmussen MA, Frost M, Budilovsky N, Kim S, Tiberg F. (2018). Quality of life according to responder rate in opioid dependent adults receiving treatment with buprenorphine depot injections (CAM2038) versus sublingual buprenorphine/naloxone. The Professional Society for Health Economics and Outcomes Research (ISPOR Europe) Annual Meeting, November 10-14, Barcelona, Spain.
  • Rasmussen MA, Frost M, Jensen R, Budilovsky N, Kim S, Tiberg F. (2018) Quality of life according to temporal illicit opioid use and responder rate in adults receiving buprenorphine depot injections (CAM2038) to treat opioid use disorder in a 48-week open label study. The Professional Society for Health Economics and Outcomes Research (ISPOR Europe) Annual Meeting, November 10-14, Barcelona, Spain.
  • Kim S, Budilovsky-Kelley N, Frost M, Lintzeris N, Bailey G, Dunlap A, Nunes N, Tiberg F. (2018) An efficacy and safety comparison of weekly/monthly ER injectable BPN (CAM2038) vs daily SL BPN/NX for treatment of pts with OUD who inject opioids or use heroin. International Society of Addiction Medicine (ISAM) Annual Meeting and Scientific Conference, November 3-6, Busan, Republic of Korea.
  • Lofwall M, Nunes E, Bailey G, Walsh S, Sigmon S, Kampman K, Frost M, Tiberg F, Kim S. (2018) Exploring opioid dependence treatment outcomes by quantitative urine analysis: A randomized, double-blind, double-dummy Phase 3 study of weekly and monthly depot buprenorphine (CAM2038) versus daily treatment with sublingual buprenorphine/naloxone. International Society of Addiction Medicine (ISAM) Annual Meeting and Scientific Conference, November 3-6, Busan, Republic of Korea.
  • Kim S, Frost M, Lintzeris N, Bailey G, Dunlop A, Budilovsky-Kelley N, Tiberg F. (2018) Converting patients from daily sublingual buprenorphine/naloxone to weekly and monthly buprenorphine injections. International Society of Addiction Medicine (ISAM) Annual Meeting and Scientific Conference, November 3-6, Busan, Republic of Korea.
  • Bailey F, Frost M, Lofwall M, Walsh S, Budilovsky-Kelley N, Tiberg F. (2018) A real-world efficacy and safety comparison of CAM2038 vs SL BPN/NX for the treatment of patients with OUD who inject opioids. The College on Problems of Drug Dependence (CPDD), June 11-12, San Diego, CA.
  • Frost M, Lofwall M, Bailey, G, Walsh S, Beacker M, Budilovsky-Kelley N, Tiberg F. (2018) Phase 3 trial comparing depot buprenorphine (CAM2038) to sublingual buprenorphine/naloxone for OUD treatment: Subanalysis among persons with heroin as the primary opioid of abuse. The College on Problems of Drug Dependence (CPDD), June 11-12, San Diego, CA.
  • Frost M, Carter J, Kim S, Budilovsky-Kelley N. (2018) Economic impact of flexible-dose depot-injectable buprenorphine versus sublingual buprenorphine/naloxone to treat opioid addiction in persons primarily abusing heroin. Academy of Managed Care Pharmacy (AMCP) Annual Meeting, April 23-26, Boston, MA.
  • Frost M, Bailey G, Kim S, Budilovsky-Kelley N. (2018) Transitioning patients from sublingual to injectable weekly and monthly buprenorphine. Annual Meeting of the American Society of Addiction Medicine (ASAM), April 12-13, San Diego, CA.

2017

  • Lofwall M, Nunes E, Bailey G, Walsh S, Sigmon S, Tiberg F, Linden M, Sheldon B, Kim S. (2017) Efficacy of Buprenorphine (BPN) depot injections vs. Sublingual BPN for opioid use disorder: A phase 3 RCT. American Academy of Addiction Psychiatry (AAAP) Annual Meeting, December 7-10 San Diego, CA.
  • Strang J, Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Kim S, Tiberg F. (2017) Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for treatment of opioid dependence: A European, Australian and U.S. Phase 3 study. Society for the Study of Addiction (SSA) Annual Conference, November 9-10, Newcastle, UK.
  • Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Strang J, Kim S, Tiberg F. (2017) Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for opioid use disorder. Lisbon Addictions, October 24-26, Lisbon, Portugal.
  • Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Strang J, Kim S, Tiberg F. (2017) Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for opioid use disorder: European and Australian experience. Addictions Toxicomanies Hepatities SIDA (ATHS) Annual Meeting, October 17-20, Biarritz, France.
  • Carter J, Frost M, Sanjurjo V. (2017) Determining the economic impact of medication non-adherence in persons treated with depot-injectable or sublingual buprenorphine for opioid use disorder. Academy of Managed Care Pharmacy Nexus (AMCP Nexus) Annual Meeting, October 16-19, Dallas, TX.
  • Carter J, Dammerman R, Frost M, Tiberg F. (2017) Employing bayesian-calibrated microsimulation to assess the cost-effectiveness of long acting injectable buprenorphine versus sublingual buprenorphine to treat opioid use disorder. Academy of Managed Care Pharmacy (AMCP) Annual Meeting, March 27-30, Denver, CO.

Define the future at Braeburn...together.

Join Our Team